An imbalance in the gut “microbiome” of people with lupus may be driving the chronic autoimmune disease as well as its flare-ups, new research suggests.
The microbiome is the trillions of helpful bacteria that co-exist in the human digestive tract and in the body.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs